VTYX - Why Ventyx Biosciences Stock Fell After-Hours | Benzinga
Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares plunged in Monday's after-hours session after the company announced results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis.
What To Know: The Phase 2 trial of VTX002 was a 13-week, randomized, double-blind, placebo-controlled, dose-ranging trial evaluating the efficacy and safety of two oral ...